Worth reading
89Important
Scored from 1 of 5 sectionsDirection
Deterioration
Direction inferred from the company’s description.Scale
14134064
SharesWording
Avoiding a definitive answer
How definitive the wording is.This transaction
This share transferCounterpartyVÕ XUÂN BỘI LÂM
Disclosing companyNissha Co.,Ltd.
The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.
Execution Date / Effective Date17 September 2026 (completion of the transfer of 14,134,064 shares). The remaining 2,826,813 shares are scheduled to be transferred between mid-September 2027 and mid-September 2028.
Consideration and expenses
Amount of extraordinary income (loss)A gain or loss on the sale of shares in an affiliate is expected to be recognized in the fiscal year ending December 2026, but the amount is currently under review.
Impact on Business Performance
The impact on the full-year consolidated earnings forecast for the fiscal year ending December 2026 is currently under review.
| Item | Details |
|---|---|
| Transaction name | This share transfer |
| Counterparty name | VÕ XUÂN BỘI LÂM |
| Name of the Subject Company | USM HEALTHCARE MEDICAL DEVICES FACTORY JOINT STOCK COMPANY |
| Voting rights ownership percentage | Before 60% → after 10% |
| Amount of extraordinary income (loss) | A gain or loss on the sale of shares in an affiliate is expected to be recognized in the fiscal year ending December 2026, but the amount is currently under review. |
| Impact on Business Performance | The impact on the full-year consolidated earnings forecast for the fiscal year ending December 2026 is currently under review. |
| Execution Date / Effective Date | 17 September 2026 (completion of the transfer of 14,134,064 shares). The remaining 2,826,813 shares are scheduled to be transferred between mid-September 2027 and mid-September 2028. |
Items this document does not state (25)
Business Description of the Subject CompanyLocation of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredFunding arrangementsGoodwill amountDate of board resolutionContract DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The implementation and completion of the share transfer have been announced, but no reason for the transfer has been provided. The gain or loss on the sale of shares in an affiliate and the impact on the consolidated earnings forecast are currently under review.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.